Survivors of Adult-onset Cancer Treated With Cisplatin Should Have Routine Auditory Exams
Survivors of adult-onset cancer who were treated with cisplatin chemotherapy should undergo routine hearing exams.
All articles by John Eckman
Candesartan Unlikely to Mitigate Cardiac Events in Patients With Early Breast Cancer Undergoing Treatment
Candesartan is unlikely to mitigate cardiotoxic effects of trastuzumab for patients with early breast cancer.
Patients With Hodgkin Lymphoma May Benefit From PET-CT Scans to Guide Treatment
Patients with advanced Hodgkin lymphoma may benefit from positron-emission tomography-computed tomography (PET-CT) testing.
Sugar-sweetened Beverages Linked to Biliary Tract Cancers
Sugary beverages may raise one’s risk of contracting gallbladder and other varieties of biliary tract cancers (BTCs).
Updated Outcomes From Multiple Myeloma Study Support New Standard of Care
Newly-diagnosed patients with multiple myeloma who are ineligible for stem-cell transplantation ought to be treated with lenalidomide plus low-dose dexamethasone.
Patients With NSCLC May Fare Better in High-volume Hospital Settings
High-volume surgical centers may improve clinical outcomes for patients with non-small-cell lung cancer (NSCLC) undergoing surgical resection.
Study Shows Feasibility of Multimodal Therapy Trials for Patients With Borderline Resectable Pancreatic Cancer
Quality-controlled trials can and ought to be conducted in multi-institutional settings on patients with borderline resectable pancreatic cancer.
Protein Expression Linked With Daratumumab Resistance for Multiple Myeloma Patients
Therapies that alter expression of the CD-38 glycoprotein and complement-inhibitory proteins (CIPs) should be studied in the treatment of multiple myeloma.
ABP 215 Displays Clinical Similarity to Bevacizumab for Patients With Non-squamous NSCLC
Biosimilar candidate ABP 215 may be clinically interchangeable with bevacizumab for treatment of non-squamous non-small cell lung cancer (NSCLC).
Regorafenib May Improve PFS for Patients With Metastatic Sarcoma
Regorafenib provides a statistically significant benefit for non-liposarcoma patients with pre-treated, metastatic sarcoma.
- Loading...
Loading...
Next post in Sarcoma Clinical Trials
Loading... 
Loading...